Literature DB >> 34261490

Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion.

Yanyan Wang1, Xiaowei Li1, Xin Chen1, Jens Nielsen1,2,3, Dina Petranovic1,2, Verena Siewers4,5.   

Abstract

Monoclonal antibodies, antibody fragments and fusion proteins derived thereof have revolutionized the practice of medicine. Major challenges faced by the biopharmaceutical industry are however high production costs, long processing times and low productivities associated with their production in mammalian cell lines. The yeast Saccharomyces cerevisiae, a well-characterized eukaryotic cell factory possessing the capacity of post-translational modifications, has been industrially exploited as a secretion host for production of a range of products, including pharmaceuticals. However, due to the incompatible surface glycosylation, few antibody molecules have been functionally expressed in S. cerevisiae. Here, three non-glycosylated antibody fragments from human and the Camelidae family were chosen for expression in a S. cerevisiae strain (HA) previously evolved for high α-amylase secretion. These included the Fab fragment Ranibizumab (Ran), the scFv peptide Pexelizumab (Pex), and a nanobody consisting of a single V-type domain (Nan). Both secretion and biological activities of the antibody fragments were confirmed. In addition, the secretion level of each protein was compared in the wild type (LA) and two evolved strains (HA and MA) with different secretory capacities. We found that the secretion of Ran and Nan was positively correlated with the strains' secretory capacity, while Pex was most efficiently secreted in the parental strain. To investigate the mechanisms for different secretion abilities in these selected yeast strains for the different antibody fragments, RNA-seq analysis was performed. The results showed that several bioprocesses were significantly enriched for differentially expressed genes when comparing the enriched terms between HA.Nan vs. LA.Nan and HA.Pex vs. LA.Pex, including amino acid metabolism, protein synthesis, cell cycle and others, which indicates that there are unique physiological needs for each antibody fragment secretion.
© 2021. The Author(s).

Entities:  

Keywords:  Pharmaceutical proteins; Protein secretion capacity; RNA-seq analysis; Saccharomyces cerevisiae

Year:  2021        PMID: 34261490     DOI: 10.1186/s12934-021-01624-0

Source DB:  PubMed          Journal:  Microb Cell Fact        ISSN: 1475-2859            Impact factor:   5.328


  54 in total

Review 1.  Engineered antibody fragments and the rise of single domains.

Authors:  Philipp Holliger; Peter J Hudson
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 2.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

3.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

4.  Antibody fragments: hope and hype.

Authors:  Aaron L Nelson
Journal:  MAbs       Date:  2010-01-27       Impact factor: 5.857

Review 5.  Coming-of-Age of Antibodies in Cancer Therapeutics.

Authors:  B Vijayalakshmi Ayyar; Sushrut Arora; Richard O'Kennedy
Journal:  Trends Pharmacol Sci       Date:  2016-10-10       Impact factor: 14.819

6.  Stable expression of chimeric heavy chain antibodies in CHO cells.

Authors:  Vishal Agrawal; Igor Slivac; Sylvie Perret; Louis Bisson; Gilles St-Laurent; Yanal Murad; Jianbing Zhang; Yves Durocher
Journal:  Methods Mol Biol       Date:  2012

Review 7.  Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions.

Authors:  Kyla R Rodgers; Richard C Chou
Journal:  Biotechnol Adv       Date:  2016-07-25       Impact factor: 14.227

8.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

Review 9.  Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells.

Authors:  Aleš Berlec; Borut Strukelj
Journal:  J Ind Microbiol Biotechnol       Date:  2013-02-06       Impact factor: 3.346

Review 10.  Recombinant Antibody Fragments for Neurodegenerative Diseases.

Authors:  Karen Manoutcharian; Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more
  2 in total

1.  CRISPR/Cas9-mediated point mutations improve α-amylase secretion in Saccharomyces cerevisiae.

Authors:  Yanyan Wang; Xiaowei Li; Xin Chen; Verena Siewers
Journal:  FEMS Yeast Res       Date:  2022-07-15       Impact factor: 2.923

Review 2.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.